[{"arm_notes": "nan", "treatment_id": null, "treatment_name": "CYNK-001", "treatment_type": "Biological", "pharmacological_treatment": "Non pharmacological treatment"}, {"arm_notes": "nan", "treatment_id": null, "treatment_name": "CYNK-001", "treatment_type": "Biological", "pharmacological_treatment": "Non pharmacological treatment"}]

[{"arm_notes": "Phase I will evaluate the safety and efficacy of multiple doses of CYNK-001 (Days 1,4, and 7) in 14 patients.", "treatment_id": 366, "treatment_name": "Cynk-001", "treatment_type": "Advanced therapy medicinal products (atmp)", "pharmacological_treatment": "Biological treatment"}, {"arm_notes": "Phase II will utilize a randomized, open-label design; multiple doses of CYNK-001 will be compared to the control group: Best Supportive Care. Up to 72 patients will be included in the Phase II portion of the study with a 1:1 randomization ratio.", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]